Page 134«..1020..133134135136..140..»

Category Archives: Cell Medicine

Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

Posted: February 3, 2012 at 11:28 am

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way.

"Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients.

"At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient.

"We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our citizens. Innovation is essential for "patient-centered" care.

"The development of new and more effective medicines and vaccines continues to change the face of health care in Canada . Canadians now survive life threatening illnesses and live with chronic conditions in ways not possible for previous generations.

"We applaud the Canadian Institutes of Health Research, Genome Canada and the Cancer Stem Cell Consortium for their vision and leadership to develop and implement a scientific innovation that will result in better health for Canadians."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

The rest is here:
Statement - Rx&D Applauds Government of Canada for Investing in Personalized Medicine

Posted in Cell Medicine | Comments Off on Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

Daniel Kraft on Singularity 1 on 1 (part 3) – Video

Posted: February 2, 2012 at 9:52 am

31-01-2012 20:35 http://www.singularityweblog.com This morning I interviewed Daniel Kraft for Singularity 1 on 1. I met Dr. Kraft at Singularity University where he is the Medicine and Neuroscience Chair and executive director of the FutureMed Program. Daniel is one of those people with an incredibly diverse spectrum of talents and interests for he is not only a medical doctor and oncologist but also an inventor, a technology and space enthusiast, an entrepreneur and an F-16 flight surgeon. During our conversation we discuss a variety of topics such as: Daniel's early interest and talent in technology and science; his original fascination with the Apollo Space program and eventual participation in International Space University; his passion for flying and being a pilot; his medical education and personal journey to becoming a faculty member at Singularity University; his desire to be an instigator, connector and motivator of innovation; the story behind as well as the purpose and structure of the FutureMed program; bone marrow harvesting, regenerative medicine and stem cell research; longevity and the future of medicine and health care; his greatest inspiration and concerns about the field of medicine and his belief that one doesn't have to be a doctor to improve health care.

View original post here:
Daniel Kraft on Singularity 1 on 1 (part 3) - Video

Posted in Cell Medicine | Comments Off on Daniel Kraft on Singularity 1 on 1 (part 3) – Video

Daniel Kraft on Singularity 1 on 1 (part 1) – Video

Posted: February 2, 2012 at 9:52 am

31-01-2012 18:50 http://www.singularityweblog.com This morning I interviewed Daniel Kraft for Singularity 1 on 1. I met Dr. Kraft at Singularity University where he is the Medicine and Neuroscience Chair and executive director of the FutureMed Program. Daniel is one of those people with an incredibly diverse spectrum of talents and interests for he is not only a medical doctor and oncologist but also an inventor, a technology and space enthusiast, an entrepreneur and an F-16 flight surgeon. During our conversation we discuss a variety of topics such as: Daniel's early interest and talent in technology and science; his original fascination with the Apollo Space program and eventual participation in International Space University; his passion for flying and being a pilot; his medical education and personal journey to becoming a faculty member at Singularity University; his desire to be an instigator, connector and motivator of innovation; the story behind as well as the purpose and structure of the FutureMed program; bone marrow harvesting, regenerative medicine and stem cell research; longevity and the future of medicine and health care; his greatest inspiration and concerns about the field of medicine and his belief that one doesn't have to be a doctor to improve health care.

See the original post here:
Daniel Kraft on Singularity 1 on 1 (part 1) - Video

Posted in Cell Medicine | Comments Off on Daniel Kraft on Singularity 1 on 1 (part 1) – Video

Dr. Ramaswamy on Targeting Dormant Cancer Cells – Video

Posted: February 2, 2012 at 9:52 am

01-02-2012 14:59 Sridhar Ramaswamy, MD, Massachusetts General Hospital Cancer Center, Assistant Professor of Medicine, Harvard Medical School, Harvard Stem Cell Institute, discusses targeting dormant cancer cells and the possible role that they play in the development of drug resistance. Dormant cells appear in most patients with tumors. These cells are not rapidly proliferating and remain largely inactive. While these cells sleep, they are highly resistant to most types of therapy. Dormant cancer cells are intrinsically intriguing because the number of inherent mutations would denote that the cells should be rapidly proliferating. The mechanism that allows them to switch between dormant and active is yet unknown. The goal of the research is to discover the underlying cause of the dormancy, tumor progression, and the mechanism of resistance to various types of therapy.

View post:
Dr. Ramaswamy on Targeting Dormant Cancer Cells - Video

Posted in Cell Medicine | Comments Off on Dr. Ramaswamy on Targeting Dormant Cancer Cells – Video

An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use – James P. Watson, MD – Video

Posted: February 1, 2012 at 6:00 pm

31-01-2012 13:32 James P. Watson, MD lecture sample from the 11th Clinical Applications for Age Management Medicine Conference, Fall 2011, Las Vegas, Nevada Pre-Conference Track 2: Regenerative and Cell Based Medicine This lecture focused on regenerative and cell-based medicine, Autologous Stem Cell Research. This field continues to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information about our upcoming conference visit our website http://www.agemed.org Or contact us at conference@agemed.org

Here is the original post:
An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video

Posted in Cell Medicine | Comments Off on An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use – James P. Watson, MD – Video

An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use – James P. Watson, MD – Video

Posted: February 1, 2012 at 1:09 pm

31-01-2012 13:32 James P. Watson, MD lecture sample from the 11th Clinical Applications for Age Management Medicine Conference, Fall 2011, Las Vegas, Nevada Pre-Conference Track 2: Regenerative and Cell Based Medicine This lecture focused on regenerative and cell-based medicine, Autologous Stem Cell Research. This field continues to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information about our upcoming conference visit our website http://www.agemed.org Or contact us at conference@agemed.org

Follow this link:
An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video

Posted in Cell Medicine | Comments Off on An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use – James P. Watson, MD – Video

Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics – Video

Posted: February 1, 2012 at 3:17 am

24-01-2012 18:39 Four minute excerpt from the Spotlight on Genomics seminar presentation during the January 17th 2012 California Institute for Regnerative Medicine governing board meeting. The video features a conversation between Catriona Jamieson, director for stem cell research at UCSD Moores Cancer Center, and one of her patients who is participating in a clinical trial for the treatment of myelofibrosis, a life-threatening blood disorder.

See original here:
Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics - Video

Posted in Cell Medicine | Comments Off on Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics – Video

‘Personalized medicine’ gets $67.5M research boost

Posted: January 31, 2012 at 6:07 pm

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

Read more:
'Personalized medicine' gets $67.5M research boost

Posted in Cell Medicine | Comments Off on ‘Personalized medicine’ gets $67.5M research boost

Biobanking for Medicine: Technology and Market 2012-2022

Posted: January 31, 2012 at 9:28 am

NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biobanking for Medicine: Technology and Market 2012-2022

http://www.reportlinker.com/p0765582/Biobanking-for-Medicine-Technology-and-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

What does the future hold for biobanks? Visiongain's report shows you potential revenues and trends to 2022. Find data, forecasts and discussions for biobanking in medicine.

Discover sales predictions at overall market, submarket and national levels to 2022. Our study gives you business research, analysis and opinion for applications in medical research, pharmaceuticals and diagnostics. 

How will the biobanking industry perform? Receive forecasts for human tissue banking, stem cell banking, private cord banking, other services (e.g., DNA and RNA storage), commercial biobanks, academic collections and other operations. You find revenues and discussions.

R&D applications are multiplying and widening. Assess contributions of biobanks in understanding disease, drug discovery, drug development and biomarkers. This decade will result in technological and organisational progress, public and private, benefiting healthcare. 

Our report discusses Cryo-Cell International, Cord Blood America, Tissue Solutions, Asterand, ViaCord, LifebankUSA, China Cord Blood and other organisations. See activities and outlooks. 

Biobanks and biorepositories will become more important to medical R&D and human healthcare. Biological science and technology stand to benefit. Discover the prospects. 

Visiongain's study provides data, analysis and opinion aiming to help your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), news and views. You receive 72 tables and charts and six research interviews.

Advantages of Biobanking for Medicine: Technology and Market 2012-2022 for your work

In particular, this study gives you the following knowledge and benefits:• Find revenue predictions to 2022 for the overall world market and submarkets, seeing growth trends• Assess companies in medical biobanking, discovering activities and outlooks• See revenue forecasts to 2022 in leading countries for human tissue banking - US, Japan, Germany,France, UK, Spain, Italy, China and India• Review developmental trends for biobanks - technologies and services• Investigate competition and opportunities influencing commercial results• Find out what will stimulate and restrain that industry and market• View expert opinions from our survey of that biotechnology sector.

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for medical biobanking Our study is for everybody needing industry and market analyses for medical biobanks. Find data, trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6 

Table of Contents1. Executive Summary

1.1 Summary Points of this Report

1.2 Aims, Scope and Format of the Report

1.2.1 Speculative Aspects of Assessing the Biobanking Market

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

1.3.1 Human Tissue Banking Market

1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking2.1 Biobanking2.1.1 Processes Involved in Biobanking2.2 Biobanks: A Two-Fold Character2.3 Key Features2.4 Classification of Biobanks2.4.1 Volunteer Groups2.4.1.1 Population-Based Biobanks2.4.1.2 Disease-Oriented Biobanks2.4.2 Ownership or Funding Structure2.5 Guidelines and Standards2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research2.5.2 Industry Standards for Biobanks2.5.3 Biobanking Processes Governed by Guidelines2.6 Laws and Regulations for Biobank-Based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry

3.1.1 Research and Drug Development

3.1.1.1 Understanding Disease Pathways

3.1.1.2 Drug Discovery

3.1.1.3 Biomarker Discovery

3.1.2 Therapeutics

3.1.3 Clinical Trials

3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking4.1 Overview4.2 Systems/Technologies4.2.1 Automated Liquid Handling4.2.1.1 Frozen Aliquotting: New Technology in Development4.2.2 Storage4.2.2.1 Ultra-Low Temperature Freezing4.2.2.2 Room-Temperature Storage4.2.3 RFID and Tagging Technologies4.3 Software4.3.1 Laboratory Information Management System (LIMS)4.3.1.1 LIMS Functions4.4 Consumables4.5 Services

5. The World Medical Biobanking Market to 2022

5.1 Current State of the Biobanking Market

5.2 Geographical Footprint

5.3 Growing Demand for Biobank Resources

5.4 Revenue Forecast for Overall Market

5.4.1 Scope and Limitations

5.4.2 Biobanking Market, 2011-2022

5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016

5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022

5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market6.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-20226.1.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-20166.1.2 Revenue Forecast for Overall Human Tissue Banking Market, 2017-20226.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2011-20226.2.1 Revenue Forecast for Commercial Human Tissue Banking Market, 2011-20166.2.2 Revenue Forecast for Commercial Human Tissue Banking Market, 2017-20226.2.3 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2011-20166.2.4 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2017-20226.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2011-20226.4 Some Commercial Participants in the Human Tissue Banking Market6.4.1 Business Models of Companies in the Biobanking Market6.4.2 Tissue Solutions6.4.2.1 Overview6.4.2.2 Global Presence6.4.2.3 Products and Services6.4.2.3.1 Banked Samples6.4.2.3.2 Prospective Samples6.4.2.3.3 Fresh Samples6.4.2.3.4 Freshly Isolated and Primary Cells6.4.2.3.5 Services6.4.2.4 Strengths and Capabilities6.4.2.5 Future Outlook6.4.3 Asterand6.4.3.1 Overview6.4.3.2 Global Presence6.4.3.3 Products and Services6.4.3.3.1 XpressBANK6.4.3.3.2 ProCURE6.4.3.3.3 PhaseZERO6.4.3.3.4 BioMAP6.4.3.4 Asterand: Raised Barriers for New Market Entrants?6.4.3.5 Financial Performance6.4.3.6 Future Outlook

7. Stem Cell Banking

7.1 Overview

7.2 Revenue Forecast for Overall Stem Cell Banking Market, 2011-2022

7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016

7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022

7.3 Stem Cell Banks for Research: High Growth Possible

7.4 Umbilical Cord Blood Banking for Stem Cells

7.4.1 Blood Banks: Private vs. Public

7.4.2 Biological Insurance: Private Blood Banking

7.4.3 Umbilical Cord Banking: The Controversies

7.4.3.1 US Oversight of Cord Blood Stem Cells

7.4.4 Revenue Forecast for Private Cord Blood Banking Market, 2011-2016

7.4.5 Revenue Forecast for Private Cord Blood Banking Market, 2017-2022

7.4.6 Companies in the Field

7.4.6.1 Cord Blood America: Looking Towards the Chinese Market

7.4.6.2 ViaCord: 145,000 Blood Units in Storage

7.4.6.3 Cryo-Cell International: The First Cord Blood Bank

7.4.6.4 Stem Cell Authority: Exclusive Stem Cells

7.4.6.5 LifebankUSA: Placenta-Cord Banking

7.4.6.6 Biogenea-Cellgenea

7.4.6.7 China Cord Blood Corp

7.4.6.8 Cryo-Save

7.4.6.9 Thermogenesis

7.5 Gene/DNA Banking

8. Industry Trends8.1 Automated Biobanking8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking8.1.2 Addressing Sample Storage and Tracking Issues8.2 Green Banking8.3 Creation of National Biobanks8.4 HIPAA Amendments

9. Qualitative Analysis of the Biobanking Sector

9.1 Strengths

9.1.1 Wealth of Information for Genetic Research

9.1.2 Potential to Change Treatments

9.1.3 Many Governments Support Biobanking

9.2 Weaknesses

9.2.1 Quality Concerns for Some Existing Biospecimen Collections

9.2.2 Lack of Standardisation and Harmonisation of Best Practices

9.2.3 Limited Sharing and Linkage of Biobanks

9.3 Opportunities

9.3.1 Genome-Wide Association Studies (GWAS)

9.3.2 Personalised Medicine

9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach

9.4 Threats

9.4.1 Ethical and Regulatory Issues

9.4.1.1 Limitations of Informed Consent in Biobanking

9.4.1.2 Confidentiality and Security to Prevent Improper Use

9.4.2 Social and Cultural Issues

9.4.3 Ownership Issues

9.4.4 Funding

10. Research Interviews from Our Survey10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry 10.1.2 On Commercial Aspects of Biobanking10.1.3 On the Business of Tissue Solutions10.1.4 On the Attractiveness of Human Tissue Banking10.1.5 On the Future of the Biobanking Market10.2 Dr Angel García Martín, Director, Inbiomed10.2.1 On the Importance of Biobanking in the Pharmaceutical Industry 10.2.2 On the Use of Technology in Biobanking 10.2.3 On Increased Recognition of Biobanking and Harmonisation of Samples 10.2.4 On the Use of Biobanks by the Pharmaceutical Industry 10.2.5 On Private Biobanks and Scale of Operations 10.2.6 On Commercial and Public Biobanking and Legislation 10.2.7 On the Most Attractive Segment in Commercial Biobanking10.2.8 On the Future of Biobanking: Drivers and Challenges10.3 Dr Piet Smet, Director, Business Development, BioStorage Technologies10.3.1 On Defining Biorepositories and Biobanks10.3.2 On the Services of Biostorage10.3.3 On Main Customers for Biostorage10.3.4 On the Importance of Biorepositories in Research and Industry10.3.5 On Technology Use in Biobanks10.3.6 On Increased Recognition of Biobanking and Harmonisation of Samples 10.3.7 On the Use of Biobanks by the Pharmaceutical Industry 10.3.8 On Private Biobanks and Scale of Operations 10.3.9 On Commercial and Public Biobanking and Legislation 10.3.10 On the Most Attractive Segment in Commercial Biobanking10.3.11 On Biobanking in 202010.3.12 On Drivers and Challenges in the Sector10.4 Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems10.4.1 On the Services of SampleNavigator10.4.2 On Main Customers for SampleNavigator10.4.3 On the Importance of Biorepositories in Research and Industry10.4.4 On Technology Use in Biobanks10.4.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.4.6 On the Use of Biobanks by the Pharmaceutical Industry 10.4.7 On Commercial Biorepositories/Banks and Scale of Operations 10.4.8 On Commercial and Public Biobanking10.4.9 On the Most Attractive Segment in Commercial Biobanking10.4.10 On Biobanking in 202010.4.11 On Drivers and Challenges in the Sector10.5 Mr Rob Fannon, Clinical Operations Manager, BioServe10.5.1 On the Services of BioServe10.5.2 On Main Customers for BioServe10.5.3 On the Importance of Biorepositories in Research and Industry10.5.4 On Technology Use in Biobanks10.5.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.5.6 On the Use of Biobanks by the Pharmaceutical Industry 10.5.7 On Commercial Biorepositories/Banks and Scale of Operations 10.5.8 On Commercial and Public Biobanking10.5.9 On the Most Attractive Segment in Commercial Biobanking10.5.10 On Biobanking in 202010.5.11 On Drivers and Challenges in the Sector10.6 Dr Frans A.L. van der Horst, Chairman, Dutch Collaborative Biobank10.6.1 On Importance of Biorepositories in Research and Industry10.6.2 On Increased Recognition of Biobanking and Harmonisation of Samples 10.6.3 On the Services of Dutch Collaborative Biobank10.6.4 On Commercial Drivers for Bio-Repositories/Biobanking Market10.6.5 On Commercial and Public Biobanking10.6.6 On Sustaining/Recovering Costs10.6.7 On the Most Attractive Segment in Commercial Biobanking10.6.8 On Ethical, Legal and Social Issues in Biorepositories/Biobanks

11. Conclusions

11.1 Biobanking for Research and Therapeutics

11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine

11.3 Commercial Drivers of the Biobanking Market

11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth

List of TablesTable 2.1 Prominent Population-Based Biobanks, 2011

Table 2.2 Prominent Disease-Oriented Biobanks, 2011

Table 2.3 Some Guidelines and Recommendations for Biobanks, 2011

Table 2.4 Laws and Regulations for Biobank-Based Research, Consent Requirements, and Privacy/ Data Protection, 2011

Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2011

Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2011

Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer Market, 2011

Table 4.3 Prominent LIMS Vendors, 2011

Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011

Table 4.5 Prominent Biorepository Service Providers, 2011

Table 5.1 Estimated Number of Biobanks in Europe, 2011

Table 5.2 Biobanking Market: Grouped Revenue Forecasts, 2010-2016

Table 5.3 Biobanking Market: Grouped Revenue Forecasts, 2017-2022

Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016

Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022

Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2016

Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2017-2022

Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2010-2016

Table 6.6 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2017-2022

Table 6.7 Some Leading Companies in the World Biobanking Market, 2011

Table 6.8 Asterand: Revenue by Segment, 2009 and 2010

Table 6.9 Asterand: Revenue by Geographical Area, 2010

Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast, 2010-2016

Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast, 2017-2022

Table 7.3 Prominent Stem Cell Banks Serving the Research Community, 2011

Table 7.4 Costs of Various Private Cord Blood Banks Worldwide, 2011

Table 7.5 Private Cord Blood Banking Market: Revenue Forecast, 2010-2016

Table 7.6 Private Cord Blood Banking Market: Revenue Forecast, 2017-2022

Table 7.7 Cord Blood Banking Market: Drivers and Restraints, 2012-2022

Table 7.8 Some Prominent Companies in the Cord Blood Banking Market, 2011

Table 7.9 Cryo-Cell International Revenue, 2009-2010

Table 7.10 China Cord Blood Corp Revenue and Subscribers, 2009-2010

Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010

Table 7.12 Cryo-Save Revenue by Region, 2010

Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and Weaknesses, 2012-2022

Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities and Threats, 2012-2022

Table 9.3 Information for a Biobank Donor, 2011

Table 11.1 Human Tissue Biobanking Market by Country, 2010, 2016, 2019 & 2022

List of FiguresFigure 2.1 Main Processes Involved in Biobanking, 2011

Figure 2.2 Classification of Biobanks, 2011

Figure 3.1 Biobanking and Pharmaceutical Development, 2011

Figure 4.1 Biobanking, Applications and Users, 2011

Figure 4.2 Functions of LIMS, 2011

Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2016

Figure 5.2 Overall Biobanking Market: Revenue Forecast, 2017-2022

Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016

Figure 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022

Figure 6.3 Human Tissue Banking Market: Forecast by Type of Biobank, 2010-2016

Figure 6.4 Human Tissue Banking Market: Forecast by Type of Biobank, 2017-2022

Figure 6.5 Human Tissue Banking Market: Share by Type of Biobank, 2010

Figure 6.6 Human Tissue Banking Market: Share by Type of Biobank, 2022

Figure 6.7 World and US Human Tissue Banking Markets: Revenue Forecasts, 2010-2022

Figure 6.8 Japan, EU 5 and Other Leading Human Tissue Banking Markets: National Revenue Forecasts, 2010-2022

Figure 6.9 Human Tissue Banking: National Market Shares, 2010

Figure 6.10 Human Tissue Banking: National Market Shares, 2016

Figure 6.11 Human Tissue Banking: National Market Shares, 2019

Figure 6.12 Human Tissue Banking: National Market Shares, 2022

Figure 6.13 Commercial Sourcing of Biological Samples, 2011

Figure 6.14 Commercial Banking of Biological Samples, 2011

Figure 6.15 Asterand: Revenues, 2009 & 2010

Figure 6.16 Asterand: Revenue Shares by Region of Destination, 2010

Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010

Figure 7.1 Stem Cell Banking Market: Revenue Forecast, 2010-2016

Figure 7.2 Stem Cell Banking Market: Revenue Forecast, 2017-2022

Figure 7.3 Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011

Figure 7.4 Cord Blood Banking Market: Revenue Forecast, 2010-2016

Figure 7.5 Cord Blood Banking Market: Revenue Forecast, 2017-2022

Figure 7.6 Cryo-Cell International Revenue, 2009-2010

Figure 7.7 China Cord Blood Corp Revenue and Subscribers, 2009-2010

Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010

Figure 7.9 Cryo-Save Revenue Shares by Region, 2010

Figure 11.1 Biobanking Market: World Sales Forecast, 2010, 2012, 2016, 2019 & 2022 

Companies ListedAbcellute

Abgene

Adnexus Therapeutics

AFNOR Groupe

AKH Biobank

AlloSource

American National Bioethics Advisory Commission 

American Type Culture Collection

Amgen

Analytical Biological Services

ARCH Venture Partners

Asterand

AstraZeneca

Australasian Biospecimen Network (ABN)

Autoscribe

AXM Pharma 

Bayer-Schering

Beckman Coulter

Beike Biotechnology 

Biobank Ireland Trust

Biobank Japan

Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) 

BioFortis

Biogen Idec

Biogenea-CellGenea 

BioLife Solutions

Biomatrica

Biopta

BioRep

BioSeek

BioServe

BioStorage LLC

BioStorage Technologies

BrainNet Europe

Caliper LifeSciences

Canadian Partnership for Tomorrow

CARTaGENE

Cellgene Corporation

Cells4Health

Chemagen

China Cord Blood Corp

Chinese Ministry of Health

CLB/Amsterdam Medical Center

CorCell

Cord Blood America

Cord Blood Registry 

CORD:USE (US Public Cord Blood Bank) 

CordLife

Cordon Vital (CBR) 

Coriell Institute for Medical Research

Council of Europe (CoE)

Covance

Cryo Bio System

Cryo-Cell International

Cryometrix

Cryo-Save

Cureline

Cybrdi

Danubian Biobank Foundation

deCODE Genetics

Department of Health (DoH, UK)

Draper Laboratory

Duke University Medical Center

Dutch Collaborative Biobank

EGeen

Eli Lilly

Eolas Biosciences 

Estonian Genome Project

EuroBioBank

European Commission (EC)

European Health Risk Monitoring (EHRM)

European Medicines Agency (EMA/EMEA)

European Union Group on Ethics (EGE)

Fisher BioServices

Fondazione I.R.C.C.S. Istituto Neurologico C. Besta

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health 

Fundación Istituto Valenciano de Oncología

Fundeni Clinical Institute

Genentech

Generation Scotland

GeneSaver

GeneSys

Genetic Association Information Network (GAIN)

Genizon Biosciences

Genome Quebec Biobank 

GenomEUtwin

Genomic Studies of Latvian Population

GenVault

German Dementia Competence Network

GlaxoSmithKline (GSK)

H. Lee Moffitt Cancer Center and Research Institute 

Hamilton

Hopital Necker Paris - Necker DNA Bank

Human Tissue Authority (HTA)

Hungarian Biobank

HUNT, Norway

ILSBio LLC

Inbiobank

Inbiomed

Indivumed

INMEGEN

Institut National de la Santé et de la Recherche Médicale (INSERM)

Integrated BioBank of Luxembourg

International Agency for Research on Cancer (IARC)

International Air Transport Association (IATA)

International Organization for Standardization (ISO)

International Society for Biological and Environmental Repositories (ISBER)

International Stem Cell Corporation

Kaiser Permanente

KORA-gen

LabVantage Solutions

LabWare

Leiden University Medical Center

LifebankUSA

LifeGene

LifeStem

Malaysian Cohort Project

Matrical Biosciences

Matrix

Medical Research Council (MRC)

Medical University of Gdansk

Merck & Co.

Merck Sharp & Dohme Limited (MSD)

Merck-Serono

Micronic

Millennium (Takeda Oncology Company)

MVE-Chart

National Cancer Institute (NCI)

National DNA Bank (US)

National Human Genome Research Institute (NHGRI)

National Institute of Environmental Health

National Institutes of Health (NIH)

National Public Health Institute 

National Research Ethics Service (NRES) 

NeoCodex

NeoStem

Neuromuscular Bank of Tissues and DNA Samples

New Brunswick Scientific

NEXUS Biosystems

Northwest Regional Development Agency

Novacare Bio-Logistics

Novartis

NUgene Project

Ocimum Biosolutions

Office of Biorepositories and Biospecimen Research (OBBR)

OnCore UK

Organisation for Economic Co-operation and Development (OECD)

OriGene

Oxagen

Pacific Bio-Material Management

PathServe

Perkin Elmer

Pfizer

Pharmagene Laboratories Trustees Limited

Polaris Ventures 

Pop-Gen (University Hospital Schleswig-Holstein)

PrecisionMed

Prevention Genetics

ProMedDx

Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)

ProteoGenex

Public Population Projects in Genomics (P3G Consortium)

Qiagen

RAND Corporation

Regenetech

REMP

Reproductive Genetics Institute (RGI)

Research Centre of Vascular Diseases, University of Milan

Rhode Island BioBank, Brown University

Roche

RTS Life Science

Saga Investments LLC

SampleNavigator Laboratory Automation Systems

Sanofi

SANYO Biomedical

Scottish Government

Seattle Genetics

Sejtbank (Hungarian Cord Blood Bank) 

SeqWright DNA Technology Services

SeraCare Life Sciences

Singapore Tissue Network

StarLIMS

Steelgate

Stem Cell Authority

Stem Cells for Safer Medicine (SC4SM)

Stem Cells Research Forum of India

Stemride International

Taiwan Biobank

Taizhou Biobank

TAP

Tecan

The Automation Partnership

The Sorenson Molecular Genealogy Foundation (SMGF)

Thermo Fisher Scientific

Thermogenesis

Tissue Bank Cryo Center (Bulgaria)

Tissue Solutions

Titan Pharmaceuticals

TotipotentSC

Trinity Biobank

Tumorothèque Necker-Entants Malades

UK Biobank

UK Stem Cell Bank

UmanGenomics

Umeå University

University Hospital Angers

University Medical Center Gent

University of Massachusetts Stem Cell Bank

University of Tuebingen, Department of Medical Genetics

US Biomax

Västerbotten County Council

ViaCord

Wellcome Trust

Wellcome Trust Case-Control Consortium (WTCCC)

Western Australian Genome Health Project

Wheaton Science International

Wisconsin International Stem Cell (WISC) Bank

World Health Organization (WHO)

Zhejiang Lukou Biotechnology Co 

To order this report:Blood Supply, Tissue Banking and Transplantation Industry: Biobanking for Medicine: Technology and Market 2012-2022

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

 

Follow this link:
Biobanking for Medicine: Technology and Market 2012-2022

Posted in Cell Medicine | Comments Off on Biobanking for Medicine: Technology and Market 2012-2022

Lecture by stem cell researcher tomorrow

Posted: January 29, 2012 at 8:06 pm

Celebrated adult stem cell researcher Shinya Yamanaka will
deliver a lecture, ‘New era of medicine with iPS cells', here
on Monday as part of a three-city lecture series. Prof.
Yamanaka's scientific breakthrough was the creation of
embryonic-like stem cells from adult skin cells.

The lecture by this Japanese physician is the third edition of
The Cell Press-TNQ India Distinguished Lectureship Series. He
will also deliver it in Chennai on February 1 and New Delhi on
February 3. The lecture series is co-sponsored by Cell Press
and TNQ Books and Journals.

Quantum leap

The stated goal of Prof. Yamanaka's laboratory has been to
generate pluripotent stem cells from human somatic cells. The
ability to re-programme adult cells back into an earlier,
undifferentiated state has helped to reshape the ethical debate
over stem cell research by providing an approach to obtain
pluripotent stem cells that need not be harvested from an
embryo.

Prof. Yamanaka, who was awarded the Albert Lasker Prize in 2009
and the Wolf Prize in 2011, is the director of the Centre for
iPS Cell Research and Application and professor at the
Institute for Frontier Medical Sciences at Kyoto University. He
is also a senior investigator at the UCSF-affiliated J. David
Gladstone Institutes and a professor of Anatomy at the
University of California in San Francisco.

Previous lectures

The inaugural speaker of the lecture series was American
biologist David Baltimore, who won the 1975 Nobel. The second
speaker was Australia-born American biological researcher
Elizabeth Blackburn, awarded the 2009 Nobel.

The lecture in Bangalore will commence at 4.30 p.m. at J.N.
Tata Auditorium, National Science Seminar Complex, Indian
Institute of Science, C.V. Raman Road.

The rest is here:
Lecture by stem cell researcher tomorrow

Posted in Cell Medicine | Comments Off on Lecture by stem cell researcher tomorrow

Page 134«..1020..133134135136..140..»